<?xml version="1.0" encoding="UTF-8"?>
<p>Such an effort, as well as others to be discussed below, provide the context for asking and discussing several key questions about vaccine development for prospective epidemics:
 <list list-type="order">
  <list-item>
   <p>Does the firm doing the development need to be non-profit or can there be a useful opportunity for a commercial firm?</p>
  </list-item>
  <list-item>
   <p>What revenues should vaccines actually launched in the case of an epidemic generateâ€”whether those revenues are covered by foundation grants, public or private insurance, or sales in the pharmaceutical market?</p>
  </list-item>
  <list-item>
   <p>Can conventional insurance assist in this development, given the interest of some commercial reinsurance firms in offering products of value when epidemics strike? These three key considerations will be discussed in what follows.</p>
  </list-item>
 </list>
</p>
